$140
Peptide · KPV10
KPV
KPV is the three-amino-acid sequence lysine-proline-valine, corresponding to the C-terminal 11–13 fragment of alpha-melanocyte-stimulating hormone.
$6010 mg
Checking stock…Service areaEligible U.S. destinations
For laboratory research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent disease.
What researchers study
KPV in context
Cell studies use KPV to examine melanocortin-related signaling, intracellular calcium responses, and inflammatory-response pathways without assuming that it reproduces the full parent peptide.
Read the full research profileTripeptide signalingMelanocortin-related pathwaysKeratinocyte modelsInflammatory-response models
Reference profile
Identity & specifications
Nominal size10 mg
Purity>99% specificationCatalog specification
Material typePeptide
Catalog codeKPV10
Reference identityL-lysyl-L-prolyl-L-valine
Molecular formulaC16H30N4O4
Molecular weight342.43 g/mol
Reference identities are provided to clarify nomenclature. Salts, counterions, hydration, and analytical conventions can affect reported formula and mass. Consult the linked public record and your own laboratory methods.
Product questions
Before adding
to your bag.
What does the listed purity mean?
It is the catalog specification used to describe the intended material standard.
Is this material intended for human or veterinary use?
No. It is sold solely for lawful laboratory research and may not be consumed, self-administered, compounded for patient use, or used in humans or animals.
Does Apex provide preparation or dosing instructions?
No. Apex does not provide reconstitution, dosing, administration, treatment, or personal-use guidance.
Related catalog records
Continue your review.
Scientific context
Use evidence with precision.
What this profile does
It identifies the material and supplies neutral catalog details useful for research planning and recordkeeping.
What it does not do
It does not establish safety, efficacy, clinical suitability, or an expected human outcome. Preclinical observations cannot be presented as consumer benefits.